Physician profile
Marisol Rivera
NPI 1245460856
$65,182.11
in general payments reported to CMS, 2019-2025
24 companies · $9,074 in 2025
The $9,074 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $524 · 2023: $25K · 2024: $30K · 2025: $9,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Travel and Lodging: $23K · Food and Beverage: $4,819 · Consulting Fee: $490 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,013.00 |
| Travel and Lodging | $23,012.80 |
| Food and Beverage | $4,818.79 |
| Consulting Fee | $490.00 |
| Education | $189.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $60,484.40 | 2023-2025 | Bavencio |
| Eisai INC. | $665.47 | 2021-2025 | |
| Janssen Biotech, INC. | $560.37 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Merck Sharp & Dohme LLC | $456.43 | 2022-2024 | Keytruda, Lynparza |
| Incyte Corporation | $435.21 | 2022-2023 | Jakafi |
| Amgen INC. | $396.54 | 2021-2025 | Blincyto, Kyprolis, Lumakras |
| Daiichi Sankyo INC. | $262.34 | 2023-2025 | Datroway, Enhertu, Injectafer |
| Abbvie INC. | $241.48 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $203.59 | 2023-2025 | Libtayo |
| Caris Mpi, INC. | $173.15 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $158.90 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $144.34 | 2022-2025 | Opdivo |
| Genentech, INC. | $136.00 | 2025 | Tecentriq |
| Astrazeneca Pharmaceuticals Lp | $130.00 | 2025 | Imfinzi |
| Immunocore Limited | $124.99 | 2025 | Kimmtrak |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $122.55 | 2024 | Ogsiveo |
| Apellis Pharmaceuticals, INC. | $117.86 | 2025 | Empaveli |
| Glaxosmithkline, LLC. | $116.21 | 2025 | Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $83.85 | 2023 | Alunbrig |
| Janssen Scientific Affairs, LLC | $56.35 | 2025 | Erleada, Balversa, Akeega |
| Novocure INC. | $48.64 | 2025 | Optune Lua (Novottf-200t) |
| Novartis Pharmaceuticals Corporation | $29.34 | 2022 | |
| Genentech USA, INC. | $17.79 | 2023 | Tecentriq, Alecensa, Rozlytrek |
| Array Biopharma INC | $16.31 | 2025 | Mektovi, Braftovi, Lorbrena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisol Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.